Eli Lilly faces its most challenging year since 2016 as high valuations and rising competition in the GLP-1 sector pressure the stock, which currently trails the broader market's 13% annual return.
Eli Lilly's stock is on track for its worst year since 2016, up only 8% versus the S&P 500's 13%, due to a high valuation near 40 times trailing earnings and rising GLP-1 competition, though its fundamentals remain strong.
Eli Lilly stock is currently on track for its worst annual performance since 2016, posting an 8% gain that lags behind the S&P 500's 13% return. While the company maintains strong fundamentals driven by GLP-1 drug demand, a high valuation of 40 times trailing earnings and intensifying market competition have tempered investor enthusiasm.
The underperformance is largely attributed to a high valuation of 40 times trailing earnings and concerns regarding future competition in the GLP-1 drug market, which may limit further upside.